Difficulty: Medium
Average Score: 78%
Practice
Which of the following drugs has demonstrated in vitro activity against Mycobacterium avium-intracellulare (MAI)?
Correct answer
B
Rationale
The correct answer is B) Clarithromycin. Clarithromycin is a macrolide antibiotic that has demonstrated in vitro activity against Mycobacterium avium-intracellulare (MAI). This bacterium is known to cause opportunistic infections in immunocompromised individuals, particularly those with HIV/AIDS.
Vancomycin (Option A) is a glycopeptide antibiotic commonly used to treat Gram-positive bacterial infections like MRSA and Enterococcus faecalis. It is not effective against MAI.
Erythromycin base (Option C) is another macrolide antibiotic similar to clarithromycin, but it is less effective against MAI compared to clarithromycin.
Troleandomycin (Option D) is a macrolide antibiotic that is not commonly used in clinical practice due to its potential for drug interactions and adverse effects. It is not a preferred agent for treating MAI infections.
Understanding the specific antimicrobial activity of different drugs is crucial in the field of medicine, especially in infectious diseases and immunology. Knowing which drugs are effective against particular pathogens allows healthcare providers to make informed treatment decisions and provide optimal care to patients. In the context of immune system drugs, selecting the right antimicrobial agent can significantly impact patient outcomes, especially in cases of opportunistic infections like MAI in immunocompromised individuals.
Vancomycin (Option A) is a glycopeptide antibiotic commonly used to treat Gram-positive bacterial infections like MRSA and Enterococcus faecalis. It is not effective against MAI.
Erythromycin base (Option C) is another macrolide antibiotic similar to clarithromycin, but it is less effective against MAI compared to clarithromycin.
Troleandomycin (Option D) is a macrolide antibiotic that is not commonly used in clinical practice due to its potential for drug interactions and adverse effects. It is not a preferred agent for treating MAI infections.
Understanding the specific antimicrobial activity of different drugs is crucial in the field of medicine, especially in infectious diseases and immunology. Knowing which drugs are effective against particular pathogens allows healthcare providers to make informed treatment decisions and provide optimal care to patients. In the context of immune system drugs, selecting the right antimicrobial agent can significantly impact patient outcomes, especially in cases of opportunistic infections like MAI in immunocompromised individuals.